Cholangioma is a broader description of biliary tract disease and is divided into two types of lesions: malignant and benign. Their survival rates are different. Generally speaking, the malignant lesions of cholangioma are bile duct cancer as well as gallbladder cancer, which is a relatively malignant disease. When this disease is detected, many patients are already in the advanced stage and few of these patients can live up to 1 year. However, if benign cholangiocarcinoma is treated properly, it is possible to survive normally. The medical description of how long to live for cholangiocarcinoma is mostly expressed in the form of 5-year survival rate and 10-year survival rate. This means that of all patients with bile duct cancer, what percentage of these people will live 5 years and what percentage of these people will live 10 years. The survival rate is related to the early detection of the disease, the location of the bile duct cancer and the treatment measures. In general, cholangiocarcinoma that receives standardized treatment, is detected early, and has a lower location has a relatively longer survival time, but the 5-year survival rate is still relatively low. The benign lesions of cholangiocarcinoma are mainly caused by obstruction of the bile duct caused by these diseases, which is detrimental to the bile drainage into the intestine and causes obstructive jaundice, resulting in liver, kidney, brain and other organ damage. Although these diseases can adversely affect the body, they are not likely to recur after standardized treatment because they are benign. Therefore, with proper treatment, it is possible to continue living a normal life. After bile duct tumor is found, detailed examination must be conducted in a regular hospital to clarify the benign and malignant nature of bile duct tumor first. We should develop a reasonable treatment plan as early as possible so as to prolong the survival time.